World Medical Marijuana Cannabidiol Pipeline Report 2021 Published

CANNANNEW REPORT

The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana – Cannabidiol pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Medical Marijuana – Cannabidiol Understanding The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD. THC can increase appetite and reduce nausea. THC may also decrease pain, inflammation (swelling and redness), and muscle control problems. Medical Marijuana – Cannabidiol Emerging Drugs BX-1: Bionorica SEBX-1 is an oral solution containing dronabinol, being developed by Bionorica. Dronabinol is a synthetic form of ??-THC, the primary psychoactive component of cannabis. The drug is currently in phase III stage of development for the treatment of spasticity in patients with multiple sclerosis not showing sufficient response to their current anti-spasticity treatment.Lenabasum: Corbus PharmaceuticalsCorbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells.THX-110: Therapix BiosciencesTHX-110 is a being developed by Therapix Biosciences.…

Excerpt only …
READ MORE BELOW
Source : World Medical Marijuana Cannabidiol Pipeline Report 2021 Published

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.